These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 32441379)

  • 1. Evolving Therapeutic Options for Chronic Graft-versus-Host Disease.
    Gonzalez RM; Pidala J
    Pharmacotherapy; 2020 Aug; 40(8):756-772. PubMed ID: 32441379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic GVHD: review advances in prevention, novel endpoints, and targeted strategies.
    Amanam I; Otoukesh S; Al Malki MM; Salhotra A
    Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):164-170. PubMed ID: 38066845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
    Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
    PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Recent advances in prevention and treatment of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation].
    Toubai T; Hosokawa Y
    Rinsho Ketsueki; 2024; 65(5):401-411. PubMed ID: 38825520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidemiology and Treatment of Chronic Graft-versus-Host Disease Post-Allogeneic Hematopoietic Cell Transplantation: A US Claims Analysis.
    Bachier CR; Aggarwal SK; Hennegan K; Milgroom A; Francis K; Dehipawala S; Rotta M
    Transplant Cell Ther; 2021 Jun; 27(6):504.e1-504.e6. PubMed ID: 34158154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Corticosteroid-Free Primary Treatment of Chronic Extensive Graft-versus-Host Disease Incorporating Rituximab.
    Solomon SR; Sizemore CA; Ridgeway M; Zhang X; Smith J; Brown S; Holland HK; Morris LE; Bashey A
    Biol Blood Marrow Transplant; 2015 Sep; 21(9):1576-82. PubMed ID: 25985915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Chronic graft-versus-host-disease involving the oral mucosa: clinical presentation and treatment].
    Elad S; Levitt M; M Y S
    Refuat Hapeh Vehashinayim (1993); 2008 Nov; 25(4):19-27, 72. PubMed ID: 19263864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IL6-receptor antibody tocilizumab as salvage therapy in severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: a retrospective analysis.
    Kattner AS; Holler E; Holler B; Klobuch S; Weber D; Martinovic D; Edinger M; Herr W; Wolff D
    Ann Hematol; 2020 Apr; 99(4):847-853. PubMed ID: 32086584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ibrutinib for the treatment of chronic graft-vs-host disease in pediatric hematopoietic stem cell transplant patients: A single-center experience.
    Teusink-Cross A; Davies SM; Grimley MS; Chandra S; Flannery A; Dandoy CE; Nelson AS; Marsh RA; Jacoby B; Lane A; Khandelwal P
    Pediatr Transplant; 2020 May; 24(3):e13692. PubMed ID: 32202691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Steroid-Refractory Chronic Graft-Versus-Host Disease: Treatment Options and Nursing Care.
    Cazeau N; Rodriguez S
    Clin J Oncol Nurs; 2023 May; 27(3):259-265. PubMed ID: 37267484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Open-Label, Single-Arm, Multicenter Study of Ibrutinib in Japanese Patients With Steroid-dependent/Refractory Chronic Graft-Versus-Host Disease.
    Doki N; Toyosaki M; Shiratori S; Osumi T; Okada M; Kawakita T; Sawa M; Ishikawa T; Ueda Y; Yoshinari N; Nakahara S
    Transplant Cell Ther; 2021 Oct; 27(10):867.e1-867.e9. PubMed ID: 34102349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ibrutinib for the treatment of patients with chronic graft-versus-host disease after failure of one or more lines of systemic therapy.
    Rahmat LT; Logan AC
    Drugs Today (Barc); 2018 May; 54(5):305-313. PubMed ID: 29911695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current Approaches for the Prevention and Treatment of Acute and Chronic GVHD.
    Olivieri A; Mancini G
    Cells; 2024 Sep; 13(18):. PubMed ID: 39329708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Donor Type and Disease Risk Predict the Success of Allogeneic Hematopoietic Cell Transplantation: A Single-Center Analysis of 613 Adult Hematopoietic Cell Transplantation Recipients Using a Modified Composite Endpoint.
    Solh M; Zhang X; Connor K; Brown S; Morris LE; Holland HK; Bashey A; Solomon SR
    Biol Blood Marrow Transplant; 2017 Dec; 23(12):2192-2198. PubMed ID: 28864140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel developments in the prophylaxis and treatment of acute GVHD.
    Jamy O; Zeiser R; Chen YB
    Blood; 2023 Sep; 142(12):1037-1046. PubMed ID: 37471585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Healthcare resource utilization and costs among patients with steroid-resistant chronic graft-versus-host disease in the United States: a retrospective claims database analysis.
    Yu J; Lal LS; Anderson A; DuCharme M; Parasuraman S; Weisdorf D
    Curr Med Res Opin; 2021 May; 37(5):755-759. PubMed ID: 33615925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Janus kinase inhibition in the treatment and prevention of graft-versus-host disease.
    De Togni E; Cole O; Abboud R
    Front Immunol; 2024; 15():1304065. PubMed ID: 38380328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Graft-versus-host disease prophylaxis with tacrolimus and mycophenolate mofetil in HLA-matched nonmyeloablative transplant recipients is associated with very low incidence of GVHD and nonrelapse mortality.
    Sabry W; Le Blanc R; Labbé AC; Sauvageau G; Couban S; Kiss T; Busque L; Cohen S; Lachance S; Roy DC; Roy J
    Biol Blood Marrow Transplant; 2009 Aug; 15(8):919-29. PubMed ID: 19589481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis in HLA matched sibling or matched unrelated donor transplant for patients with acute leukemia, on behalf of ALWP-EBMT.
    Ruggeri A; Labopin M; Bacigalupo A; Afanasyev B; Cornelissen JJ; Elmaagacli A; Itälä-Remes M; Blaise D; Meijer E; Koc Y; Milpied N; Schouten HC; Kroeger N; Mohty M; Nagler A
    J Hematol Oncol; 2018 Mar; 11(1):40. PubMed ID: 29544522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.